SXTC (China SXT Pharmaceuticals) Ending Cash Position: $28.18 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is China SXT Pharmaceuticals Ending Cash Position?

China SXT Pharmaceuticals SXTC +64.13% Ending Cash Position is $28.18 Mil as of Mar. 2026. The stock has 8 warning signs investors should review.

China SXT Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $28.18 Mil.

China SXT Pharmaceuticals's quarterly Ending Cash Position increased from Mar. 2025 ($18.13 Mil) to Sep. 2025 ($21.20 Mil) and increased from Sep. 2025 ($21.20 Mil) to Mar. 2026 ($28.18 Mil).

China SXT Pharmaceuticals's annual Ending Cash Position increased from Mar. 2024 ($12.08 Mil) to Mar. 2025 ($18.13 Mil) and increased from Mar. 2025 ($18.13 Mil) to Mar. 2026 ($28.18 Mil).

China SXT Pharmaceuticals Ending Cash Position Related Terms

China SXT Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals Ending Cash Position Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.57 17.37 12.08 18.13 28.18

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.08 18.51 18.13 21.20 28.18

China SXT Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

China SXT Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=18.128+10.048
=28.18

China SXT Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=21.197+6.979
=28.18

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $28.18 Mil mean?
China SXT Pharmaceuticals (SXTC) has a Ending Cash Position of $28.18 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on China SXT Pharmaceuticals and its competitors.
Is China SXT Pharmaceuticals' Ending Cash Position too high?
China SXT Pharmaceuticals' current Ending Cash Position is $28.18 Mil.
How does China SXT Pharmaceuticals' Ending Cash Position compare to CBIH and UPC?
China SXT Pharmaceuticals' Ending Cash Position of $28.18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on China SXT Pharmaceuticals and its competitors. China SXT Pharmaceuticals's current Ending Cash Position is $28.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (SXTC) is currently considered Possible Value Trap. The stock's GF Value™ is $2.05, compared to a current price of $0.12 — trading 94% below its estimated fair value. The current Ending Cash Position is $28.18 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current Ending Cash Position is $28.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China SXT Pharmaceuticals Business Description

Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.